142 related articles for article (PubMed ID: 25529566)
1. Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity.
Zaman M; Chandrudu S; Giddam AK; Reiman J; Skwarczynski M; McPhun V; Moyle PM; Batzloff MR; Good MF; Toth I
Nanomedicine (Lond); 2014 Dec; 9(17):2613-24. PubMed ID: 25529566
[TBL] [Abstract][Full Text] [Related]
2. Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.
Marasini N; Giddam AK; Khalil ZG; Hussein WM; Capon RJ; Batzloff MR; Good MF; Toth I; Skwarczynski M
Nanomedicine (Lond); 2016 Dec; 11(24):3223-3235. PubMed ID: 27830630
[TBL] [Abstract][Full Text] [Related]
3. Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus.
Marasini N; Giddam AK; Ghaffar KA; Batzloff MR; Good MF; Skwarczynski M; Toth I
Nanomedicine (Lond); 2016 May; 11(10):1223-36. PubMed ID: 27077314
[TBL] [Abstract][Full Text] [Related]
4. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
[TBL] [Abstract][Full Text] [Related]
5. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
[TBL] [Abstract][Full Text] [Related]
7. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
8. The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.
Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Med Chem; 2016; 13(1):22-27. PubMed ID: 27449794
[TBL] [Abstract][Full Text] [Related]
9. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.
Ghaffar KA; Marasini N; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2016 Sep; 41():161-8. PubMed ID: 27063491
[TBL] [Abstract][Full Text] [Related]
10. Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant.
Azmi F; Ahmad Fuaad AA; Giddam AK; Batzloff MR; Good MF; Skwarczynski M; Toth I
Bioorg Med Chem; 2014 Nov; 22(22):6401-8. PubMed ID: 25438764
[TBL] [Abstract][Full Text] [Related]
11. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
[TBL] [Abstract][Full Text] [Related]
12. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.
Zaman M; Abdel-Aal AB; Fujita Y; Phillipps KS; Batzloff MR; Good MF; Toth I
PLoS One; 2012; 7(1):e30146. PubMed ID: 22253911
[TBL] [Abstract][Full Text] [Related]
13. Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.
Nevagi RJ; Khalil ZG; Hussein WM; Powell J; Batzloff MR; Capon RJ; Good MF; Skwarczynski M; Toth I
Acta Biomater; 2018 Oct; 80():278-287. PubMed ID: 30266637
[TBL] [Abstract][Full Text] [Related]
14. FbaA- and M protein-based multi-epitope vaccine elicits strong protective immune responses against group A streptococcus in mouse model.
Ma C; Liu Z; Li W; Qian X; Zhang S; Gao X; Jiang S; Wei L
Microbes Infect; 2014 May; 16(5):409-18. PubMed ID: 24704476
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of group A streptococcus lipopeptide vaccine candidates in trimethyl chitosan-based self-adjuvanting delivery system.
Nevagi RJ; Dai W; Khalil ZG; Hussein WM; Capon RJ; Skwarczynski M; Toth I
Eur J Med Chem; 2019 Oct; 179():100-108. PubMed ID: 31247372
[TBL] [Abstract][Full Text] [Related]
16. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a divalent group A streptococcal vaccine.
Ding Y; Ni Q; Liu J; Yu B
Rheumatol Int; 2013 Apr; 33(4):1013-20. PubMed ID: 22872049
[TBL] [Abstract][Full Text] [Related]
18. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
[TBL] [Abstract][Full Text] [Related]
19. Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines.
Moyle PM; Dai W; Zhang Y; Batzloff MR; Good MF; Toth I
Bioconjug Chem; 2014 May; 25(5):965-78. PubMed ID: 24712905
[TBL] [Abstract][Full Text] [Related]
20. Peptide amphiphile micelles self-adjuvant group A streptococcal vaccination.
Trent A; Ulery BD; Black MJ; Barrett JC; Liang S; Kostenko Y; David NA; Tirrell MV
AAPS J; 2015 Mar; 17(2):380-8. PubMed ID: 25527256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
